spacer
spacer
Learning Objectives
spacer


(CME Expired)

Goal and Statement of Need

Of the approximately 17 000 primary brain tumors diagnosed each year in the United States, 60% are gliomas. Glioblastoma multiforme (GBM) is the most common and the most malignant of the gliomas. GBM accounts for 12% to 15% of all brain tumors in adults and more than 50% of all primary brain tumors. GBM differs from anaplastic astrocytoma only by the presence of necrosis seen under the microscope in GBM. Other glioma variants include gliosarcoma, multifocal GBM, and gliomatosis cerebri (tumor involving the entire cerebrum). Prognosis with these tumors is poor and does not differ much between variants. The median survival from diagnosis is less than 1 year with very few surviving more than 3 years. This program strives to address this need by providing neuro-oncologists and radiation oncologists with up-to-date information regarding the diagnosis, management, and treatment of patients with central nervous system malignancies.

Target Audience
This activity is designed for neuro-oncologists and radiation oncologists who diagnose, manage, and treat patients with central nervous system malignancies. No prerequisites required.

Learning Objectives
After completing the module, the participant should be able to:

  • Discuss the latest trends in diagnosing central nervous system (CNS) malignancies.
  • Identify how various factors affect the prognosis of CNS malignancies.
  • Evaluate novel treatment strategies and emerging agents for the management of gliomas.
  • Differentiate among and apply the least invasive techniques for re-irradiation of gliomas.
  • Describe the heterogeneity within tumor types and the key factors to consider when developing treatment plans tailored to individual patients.
  • Incorporate information and conclusions from recent clinical trials into daily clinical practice, especially the management of gliomas.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Presented by The Johns Hopkins University School of Medicine.

spacer
Introduction and Method of Participation
spacer

In the following 4 podcasts, Martin J. van den Bent, MD, PhD, of Erasmus University Medical Center, and W. K. Alfred Yung, MD, of MD Anderson Cancer Center, provide additional insights into the content of the PCNSM4: Perspectives in Central Nervous System Malignancies conference, which they chaired. The annual PCNSM conference was held March 28-29, 2008, in Berlin, Germany, and is developed and planned by Imedex®. This meeting covered a variety of topics, including the latest trends in diagnosis and prognosis for central nervous system (CNS) malignancies, novel treatment strategies for the management of gliomas, and controversies associated with the management of some CNS malignancies. Each podcast is moderated by Stuart A. Grossman, MD, from The Johns Hopkins University School of Medicine, who participated in the meeting and serves as a Course Director of this program with Dr. van den Bent and Dr. Yung.  After listening to all 4 podcasts, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.

spacer
spacer
CME Information
spacer

Accreditation Statement: The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement: The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date: May 31, 2008. Expiration date: May 31, 2010.

Estimated time to complete activity: 1 hour

Disclaimer: The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

spacer
Course Directors
spacer

Full Disclosure Policy Affecting CME Activities: As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Directors reported the following:

Stuart A. Grossman, MD
Professor, Oncology, Medicine, and Neurosurgery
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Grossman reports having no significant financial or advisory relationships with
corporate organizations related to this activity.

Martin J. van den Bent, MD, PhD
Professor, Department of Neuro-Oncology
Daniel den Hoed Cancer Center
Erasmus University Medical Center
Rotterdam, The Netherlands
Dr van den Bent reports receiving grants/research support from Novartis
Pharmaceuticals Corporation; serving as a consultant for Adnexus, Novartis
Pharmaceuticals Corporation, and Schering-Plough Corporation; and serving on the
speakers’ bureau for Schering-Plough Corporation.

W. K. Alfred Yung, MD
Chairman, Department of Neuro-Oncology
Margaret and Ben Love Chair of Clinical Cancer Care
MD Anderson Cancer Center
Houston, Texas
Dr Yung reports receiving grants/research support from Genentech, Inc, Novartis
Pharmaceuticals Corporation, and Schering-Plough Corporation; serving as a consultant
for and receiving honoraria from Myriad, Novartis Pharmaceuticals Corporation, and Schering-Plough Corporation; and serving on the speakers’ bureau for Schering-Plough Corporation.

Off-Label Product Discussion: All faculty have indicated that they have not referenced unlabeled or unapproved uses of drugs or devices.

Supported by an educational grant from Schering-Plough.

spacer
Podcasts
spacer
 
Diagnosis and Prognosis: Optimal Approaches to Assessing MGMT Expression
Stuart A. Grossman, MD, Moderator
Martin J. van den Bent, MD, PhD, Participant
 
High-Grade Gliomas: Pseudo-Progression After Radiotherapy and Temozolomide: Is It of Clinical Significance? and Pitfalls in Response Assessment
Stuart A. Grossman, MD, Moderator
Martin J. van den Bent, MD, PhD, Participant

 
Emerging Therapies: Targeting the PI3 Kinase Pathway and Immunotherapy: Alive and Kicking?
Stuart A. Grossman, MD, Moderator
W. K. Alfred Yung, MD, Participant

 
Controversies in Neuro-Oncology: Re-Irradiation in Recurrent GBM
Stuart A. Grossman, MD, Moderator
W. K. Alfred Yung, MD, Participant

spacer
spacer

 

     
Home | Contact Us | View Account | Need Help?